Loading...
•
Jun 30, 2020
Omeros Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020.
Key Takeaways
Omeros Corporation reported a decrease in revenue for Q2 2020 to $13.5 million, compared to $26.8 million in Q2 2019. The net loss for the quarter was $33.3 million, or $0.61 per share, compared to a net loss of $14.5 million, or $0.29 per share, for the same period in 2019. The revenue decrease was due to the postponement of cataract procedures due to COVID-19.
Revenues for the second quarter of 2020 were $13.5 million, compared to $26.8 million in the second quarter of 2019.
Net loss in the second quarter of 2020 was $33.3 million, or $0.61 per share.
Six COVID-19 patients in Italy with ARDS were treated with narsoplimab under a compassionate use program, and all recovered and survived.
Omeros completed submission to FDA of the CMC information for the Company’s rolling BLA for narsoplimab for the treatment of HSCT-TMA.
Forward Guidance
Omeros is targeting this quarter for the completion of the BLA, and preparations for anticipated commercial launch are proceeding well. The company also reached a key milestone in its OMS906 program, with the on-schedule submission of the clinical trial application.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...